POTS
MCID: PST048
MIFTS: 46

Postural Orthostatic Tachycardia Syndrome (POTS)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Postural Orthostatic Tachycardia Syndrome

MalaCards integrated aliases for Postural Orthostatic Tachycardia Syndrome:

Name: Postural Orthostatic Tachycardia Syndrome 12 20 53 44 15 70
Familial Orthostatic Tachycardia Due to Norepinephrine Transporter Deficiency 12 20
Postural Tachycardia Syndrome Due to Net Deficiency 12 20
Orthostatic Intolerance Due to Net Deficiency 12 20
Mitral Valve Prolapse Syndrome 12 70
Postural Tachycardia Syndrome 20 53
Neurocirculatory Asthenia 12 70
Irritable Heart 12 70
Postural Orthostatic Tachycardia Syndrome Due to Net Deficiency 20
Chronic Othostatic Intolerance 20
Pots Due to Net Deficiency 20
Orhtostatic Intolerance 12
Soldiers Heart 12
Pots 20

Classifications:



External Ids:

Disease Ontology 12 DOID:0111154
MeSH 44 D054972
ICD10 32 I95.1
UMLS 70 C0026267 C0027821 C1299624 more

Summaries for Postural Orthostatic Tachycardia Syndrome

NINDS : 53 Postural orthostatic tachycardia syndrome (POTS) is one of a group of disorders that have orthostatic intolerance (OI) as their primary symptom. OI describes a condition in which an excessively reduced volume of blood returns to the heart after an individual stands up from a lying down position. The primary symptom of OI is lightheadedness or fainting. In POTS, the lightheadedness or fainting is also accompanied by a rapid increase in heartbeat of more than 30 beats per minute, or a heart rate that exceeds 120 beats per minute, within 10 minutes of rising. The faintness or lightheadedness of POTS are relieved by lying down again. Anyone at any age can develop POTS, but the majority of individuals affected (between 75 and 80 percent) are women between the ages of 15 to 50 years of age. Some women report an increase in episodes of POTS right before their menstrual periods. POTS often begins after a pregnancy, major surgery, trauma, or a viral illness. It may make individuals unable to exercise because the activity brings on fainting spells or dizziness. Doctors aren't sure yet what causes the reduced return of blood to the heart that occurs in OI, or why the heart begins to beat so rapidly in POTS.  Current thinking is that there are a number of mechanisms.  Some individuals have peripheral denervation (neuropathic POTS); some have symptoms that are due to sustained or parosyxmal overactivity of the sympathetic nervous system (hyperadrenergic POTS); and many individuals with POTS have significant deconditioning.

MalaCards based summary : Postural Orthostatic Tachycardia Syndrome, also known as familial orthostatic tachycardia due to norepinephrine transporter deficiency, is related to orthostatic intolerance and mitral valve insufficiency, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Postural Orthostatic Tachycardia Syndrome is SLC44A1 (Solute Carrier Family 44 Member 1), and among its related pathways/superpathways are Elastic fibre formation and G-protein signaling_Rap2B regulation pathway. The drugs Cefdinir and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include heart, eye and temporal lobe.

Disease Ontology : 12 A heart conduction disease characterized by orthostatic intolerance that has material basis in heterozygous mutation in the SLC6A2 gene on chromosome 16q12.2.

GARD : 20 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 443236 Definition A rare, genetic, primary orthostatic disorder characterized by dizziness, palpitations, fatigue, blurred vision and tachycardia following postural change from a supine to an upright position, in the absence of hypotension. A syncope with transient cognitive impairment and dyspnea may also occur. The norepinephrine transporter deficiency leads to abnormal uptake and high plasma concentrations of norepinephrine.

Wikipedia : 73 Postural orthostatic tachycardia syndrome (POTS) is a condition in which a change from lying to standing... more...

Related Diseases for Postural Orthostatic Tachycardia Syndrome

Diseases related to Postural Orthostatic Tachycardia Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 213, show less)
# Related Disease Score Top Affiliating Genes
1 orthostatic intolerance 32.4 SLC6A2 REN FBN2 FBN1
2 mitral valve insufficiency 31.1 REN FBN1
3 hypermobile ehlers-danlos syndrome 30.8 FKBP14 FBN1
4 isolated ectopia lentis 29.3 TBRG1 SAP30L MFAP3 FBN2 FBN1 FAM114A2
5 syncope 11.5
6 autonomic dysfunction 11.4
7 dysautonomia 11.4
8 mitral valve prolapse, familial, x-linked 11.4
9 chronic orthostatic intolerance 11.4
10 fainting 11.4
11 hereditary alpha tryptasemia syndrome 11.3
12 autonomic nervous system disease 11.3
13 neurotic disorder 10.8
14 pure autonomic failure 10.8
15 ehlers-danlos syndrome 10.7
16 chronic fatigue syndrome 10.7
17 dystonia 10.6
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.6
19 infective endocarditis 10.5
20 autonomic neuropathy 10.5
21 chronic pain 10.5
22 endocarditis 10.5
23 migraine with or without aura 1 10.4
24 mast cell activation syndrome 10.4
25 headache 10.4
26 marfan syndrome 10.4
27 cardiac conduction defect 10.4
28 anxiety 10.4
29 ehlers-danlos syndrome, hypermobility type 10.4
30 hypermobility syndrome 10.4
31 panic disorder 10.4
32 fibromyalgia 10.4
33 cardiac arrest 10.3
34 pectus excavatum 10.3
35 heart valve disease 10.3
36 graves disease 1 10.3
37 lyme disease 10.3
38 brugada syndrome 10.3
39 storage pool platelet disease 10.3
40 multiple sclerosis 10.3
41 constipation 10.3
42 homocystinuria 10.3
43 hypoglycemia 10.3
44 raynaud phenomenon 10.3
45 tremor 10.3
46 neuropathy 10.3
47 aortic aneurysm, familial thoracic 2 10.3 FBN2 FBN1
48 tricuspid valve prolapse 10.2 FBN2 FBN1
49 pulmonary valve insufficiency 10.2 REN FBN1
50 atrioventricular block 10.2
51 cardiac arrhythmia 10.2
52 heart septal defect 10.2
53 atrial heart septal defect 10.2
54 mitral valve disease 10.2
55 osteochondrosis 10.2
56 marden-walker syndrome 10.2 FBN2 FBN1
57 body mass index quantitative trait locus 1 10.2
58 erythermalgia, primary 10.2
59 atrial standstill 1 10.2
60 sleep disorder 10.2
61 tricuspid valve disease 10.2 REN FBN1
62 tricuspid valve insufficiency 10.1 REN FBN1
63 aortic valve insufficiency 10.1 REN FBN2 FBN1
64 sleep apnea 10.1
65 pain agnosia 10.1
66 scoliosis 10.1
67 covid-19 10.1
68 aortic dissection 10.1
69 venous insufficiency 10.1
70 dry eye syndrome 10.1
71 idiopathic peripheral autonomic neuropathy 10.1
72 gastroparesis 10.1
73 esophagitis 10.1
74 hypertrophic cardiomyopathy 10.1
75 vitamin b12 deficiency 10.1
76 exanthem 10.1
77 restless legs syndrome 10.1
78 angina pectoris 10.1
79 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.1
80 cyanosis, transient neonatal 10.1
81 esophagitis, eosinophilic, 1 10.1
82 resting heart rate, variation in 10.1
83 ventricular fibrillation, paroxysmal familial, 1 10.1
84 celiac disease 1 10.1
85 coarctation of aorta 10.1
86 autoimmune disease 10.1
87 pfeiffer syndrome 10.1
88 guillain-barre syndrome 10.1
89 squamous cell papilloma 10.1
90 conversion disorder 10.1
91 epilepsy 10.1
92 telogen effluvium 10.1
93 focal epilepsy 10.1
94 sensory peripheral neuropathy 10.1
95 hemangioma 10.1
96 papilloma 10.1
97 severe acute respiratory syndrome 10.1
98 complex regional pain syndrome 10.1
99 central nervous system disease 10.1
100 temporal lobe epilepsy 10.1
101 aortic aneurysm 10.1
102 gastritis 10.1
103 intracranial hypotension 10.1
104 myocarditis 10.1
105 choline deficiency disease 10.1
106 nervous system disease 10.1
107 eating disorder 10.1
108 neuromyelitis optica 10.1
109 irritable bowel syndrome 10.1
110 48,xyyy 10.1
111 myalgic encephalomyelitis/chronic fatigue syndrome 10.1
112 new daily-persistent headache 10.1
113 primary orthostatic hypotension 10.1
114 aneurysm 10.1
115 posttransplant acute limbic encephalitis 10.1
116 acute pandysautonomia 10.1
117 primary eosinophilic gastrointestinal disease 10.1
118 spontaneous intracranial hypotension 10.1
119 attention deficit-hyperactivity disorder 10.1
120 peripheral nervous system disease 10.1
121 narcolepsy 10.1
122 enophthalmos 10.1 FBN2 FBN1
123 post-traumatic stress disorder 10.1
124 charcot-marie-tooth disease 10.1
125 tooth disease 10.1
126 coronary artery vasospasm 10.1
127 allergic disease 10.1
128 rheumatic heart disease 10.1
129 sinoatrial node disease 10.1
130 rheumatic fever-related antigen 10.1
131 graves' disease 10.1
132 sick sinus syndrome 10.1
133 generalized anxiety disorder 10.1
134 hypothyroidism 10.1
135 rheumatic fever 10.1
136 pericarditis 10.1
137 long qt syndrome 10.1
138 intracranial embolism 10.1
139 subacute bacterial endocarditis 10.1
140 agoraphobia 10.1
141 muscular dystrophy 10.1
142 chaotic atrial tachycardia 10.1
143 progressive muscular dystrophy 10.1
144 multifocal atrial tachycardia 10.1
145 brucellosis 10.1
146 social phobia 10.1
147 spinal arachnoiditis 10.1
148 panic disorder 1 10.1
149 mitral valve prolapse 1 10.1
150 hypertriglyceridemia, familial 10.1
151 hypertension, essential 10.1
152 hypercholesterolemia, familial, 1 10.1
153 arachnoiditis 10.1
154 hypochondriasis 10.1
155 bronchitis 10.1
156 hyperthyroidism 10.1
157 47,xyy 10.1
158 geleophysic dysplasia 1 10.0 TBRG1 FBN1
159 geleophysic dysplasia 2 10.0 TBRG1 FBN1
160 tracheal stenosis 10.0 TBRG1 FBN1
161 tracheal disease 10.0 TBRG1 FBN1
162 long covid 10.0
163 pre-eclampsia 10.0
164 penile cancer 10.0
165 low compliance bladder 10.0
166 segmental dystonia 10.0
167 deficiency anemia 10.0
168 ifap syndrome 2 10.0
169 body mass index quantitative trait locus 19 10.0
170 body mass index quantitative trait locus 18 10.0
171 peripartum cardiomyopathy 10.0
172 body mass index quantitative trait locus 14 10.0
173 body mass index quantitative trait locus 12 10.0
174 body mass index quantitative trait locus 7 10.0
175 body mass index quantitative trait locus 10 10.0
176 body mass index quantitative trait locus 4 10.0
177 allergic rhinitis 10.0
178 body mass index quantitative trait locus 8 10.0
179 body mass index quantitative trait locus 9 10.0
180 stroke, ischemic 10.0
181 body mass index quantitative trait locus 11 10.0
182 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
183 syringomyelia, noncommunicating isolated 10.0
184 motion sickness 10.0
185 multiple system atrophy 1 10.0
186 common variable immunodeficiency 10.0
187 eclampsia 10.0
188 ventricular septal defect 10.0
189 iron metabolism disease 10.0
190 dermatitis 10.0
191 antiphospholipid syndrome 10.0
192 food allergy 10.0
193 syringomyelia 10.0
194 mastocytosis 10.0
195 rhinitis 10.0
196 somatoform disorder 10.0
197 connective tissue disease 10.0
198 thyroiditis 10.0
199 erythromelalgia 10.0
200 broken heart syndrome 10.0
201 chiari malformation 10.0
202 syringobulbia 10.0
203 brain injury 10.0
204 dysphagia 10.0
205 malignant tumor of penis 10.0
206 stiff skin syndrome 9.9 TBRG1 FBN2 FBN1
207 acromicric dysplasia 9.9 TBRG1 FBN2 FBN1
208 contractural arachnodactyly, congenital 9.9 FBN2 FBN1
209 geleophysic dysplasia 9.9 TBRG1 FBN2 FBN1
210 weill-marchesani syndrome 9.9 TBRG1 FBN2 FBN1
211 dysentery 9.8
212 traumatic brain injury 9.8
213 loeys-dietz syndrome 9.8 FKBP14 FBN2 FBN1

Comorbidity relations with Postural Orthostatic Tachycardia Syndrome via Phenotypic Disease Network (PDN): (showing 6, show less)


Anxiety Dysthymic Disorder
Esophagitis Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome

Graphical network of the top 20 diseases related to Postural Orthostatic Tachycardia Syndrome:



Diseases related to Postural Orthostatic Tachycardia Syndrome

Symptoms & Phenotypes for Postural Orthostatic Tachycardia Syndrome

UMLS symptoms related to Postural Orthostatic Tachycardia Syndrome:


angina pectoris; chest pain; edema

Drugs & Therapeutics for Postural Orthostatic Tachycardia Syndrome

Drugs for Postural Orthostatic Tachycardia Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 173, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefdinir Approved Phase 4 91832-40-5 6915944
2
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
3
Cefazolin Approved Phase 4 25953-19-9 656510 33255
4
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
5
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
6
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
7
Sulfamethoxazole Approved Phase 4 723-46-6 5329
8
Bisoprolol Approved Phase 4 66722-44-9 2405
9
Tranexamic Acid Approved Phase 4 1197-18-8 5526
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Folic Acid Antagonists Phase 4
12 Cephalosporins Phase 4
13 Vitamin B9 Phase 4
14 Antiparasitic Agents Phase 4
15 cefuroxime axetil Phase 4
16 Folate Phase 4
17 Vitamin B Complex Phase 4
18 Antimalarials Phase 4
19 Antiprotozoal Agents Phase 4
20 Clindamycin phosphate Phase 4
21 Clindamycin palmitate Phase 4
22 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
23 Cytochrome P-450 Enzyme Inhibitors Phase 4
24 Pharmaceutical Solutions Phase 4
25 Anti-Bacterial Agents Phase 4
26 Antibiotics, Antitubercular Phase 4
27 Coagulants Phase 4
28 Antifibrinolytic Agents Phase 4
29 Hemostatics Phase 4
30
Cycloserine Approved Phase 3 68-41-7 401 6234
31
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
32
Carbidopa Approved Phase 2, Phase 3 28860-95-9 34359
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
34
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
35 Plasma Substitutes Phase 3
36 Vitamins Phase 3
37 Hydroxycholecalciferols Phase 3
38 Calciferol Phase 3
39 Antimetabolites Phase 3
40 Antitubercular Agents Phase 3
41 Anti-Infective Agents Phase 3
42 Mitogens Phase 2, Phase 3
43 insulin Phase 2, Phase 3
44 Caseins Phase 2, Phase 3
45 Insulin, Globin Zinc Phase 2, Phase 3
46 Dopamine Agents Phase 2, Phase 3
47 Aromatic Amino Acid Decarboxylase Inhibitors Phase 2, Phase 3
48
Metoprolol Approved, Investigational Phase 2 51384-51-1, 37350-58-6 4171
49
Droxidopa Approved, Investigational Phase 1, Phase 2 23651-95-8 443940
50
Iron Approved Phase 1, Phase 2 7439-89-6 23925 29936
51
Atenolol Approved Phase 1, Phase 2 29122-68-7 2249
52
Lactoferrin Investigational Phase 2 151186-19-5
53 Muramidase Phase 2
54 Cholinesterase Inhibitors Phase 2
55 Cholinergic Agents Phase 2
56 Bromides Phase 2
57 Pyridostigmine Bromide Phase 2 101-26-8
58 Anticonvulsants Phase 2
59 Immunologic Factors Phase 1, Phase 2
60 Rho(D) Immune Globulin Phase 1, Phase 2
61 Immunoglobulins Phase 1, Phase 2
62 Immunoglobulins, Intravenous Phase 1, Phase 2
63 Antibodies Phase 1, Phase 2
64 gamma-Globulins Phase 1, Phase 2
65 Antihypertensive Agents Phase 1, Phase 2
66 Sympatholytics Phase 1, Phase 2
67 Anti-Arrhythmia Agents Phase 1, Phase 2
68 Neurotransmitter Agents Phase 1, Phase 2
69 Antiparkinson Agents Phase 1, Phase 2
70 Adrenergic Antagonists Phase 1, Phase 2
71 Adrenergic beta-Antagonists Phase 1, Phase 2
72 Adrenergic Agents Phase 1, Phase 2
73 Adrenergic beta-1 Receptor Antagonists Phase 1, Phase 2
74 Ferric Oxide, Saccharated Phase 1, Phase 2
75 Hematinics Phase 1, Phase 2
76
Angiotensin II Approved, Investigational Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198
77
Methyldopa Approved Phase 1 555-30-6 38853
78
Trimethaphan Approved, Investigational Phase 1 7187-66-8 23576
79
Galantamine Approved Phase 1 357-70-0 9651
80 Serine Proteinase Inhibitors Phase 1
81 Giapreza Phase 1
82 Angiotensinogen Phase 1
83 HIV Protease Inhibitors Phase 1
84
protease inhibitors Phase 1
85 acivicin Phase 1
86 Anesthetics Phase 1
87 Trimethaphan camsylate Phase 1
88 Cholinergic Antagonists Phase 1
89 Complement System Proteins Phase 1
90 Nootropic Agents Phase 1
91
Serine Investigational, Nutraceutical Phase 1 56-45-1 5951
92
Gabapentin Approved, Investigational 60142-96-3 3446
93
Losartan Approved Early Phase 1 114798-26-4 3961
94
Levodopa Approved Early Phase 1 59-92-7 6047
95
Citalopram Approved 59729-33-8 2771
96
Nadroparin Approved, Investigational
97
Tinzaparin Approved 9041-08-1, 9005-49-6 25244225
98
Dalteparin Approved 9005-49-6
99
Ethanol Approved 64-17-5 702
100
Hydrogen peroxide Approved, Vet_approved 7722-84-1 784
101
Lactulose Approved Early Phase 1 4618-18-2 11333
102
Digoxin Approved Early Phase 1 20830-75-5 30322 2724385
103
Propranolol Approved, Investigational 525-66-6 4946
104
Atropine Approved, Vet_approved 5908-99-6, 51-55-8 174174
105
Wormwood Approved, Experimental
106
Silicon Approved, Investigational 7440-21-3 4082203
107
Carbon monoxide Approved, Investigational 630-08-0 281
108
Nitric Oxide Approved Early Phase 1 10102-43-9 145068
109
Modafinil Approved, Investigational Early Phase 1 68693-11-8 4236
110
Cosyntropin Approved 16960-16-0 16129617
111
Nitroprusside Approved, Investigational Early Phase 1 15078-28-1 11963622
112
Norepinephrine Approved 51-41-2 439260
113
Acetylcholine Approved, Investigational 51-84-3 187
114
Phenylephrine Approved 59-42-7 6041
115
Ephedrine Approved 299-42-3 9294
116
Oxymetazoline Approved, Investigational 1491-59-4 4636
117
Isoproterenol Approved, Investigational 7683-59-2 3779
118
Pseudoephedrine Approved 90-82-4 7028
119
Moxonidine Approved, Investigational Early Phase 1 75438-57-2 4810
120
Vitamin C Approved, Nutraceutical Early Phase 1 50-81-7 5785 54670067
121
Inulin Approved, Investigational, Nutraceutical 9005-80-5 24763
122
Trichostatin A Experimental 58880-19-6
123
Dexetimide Withdrawn 21888-98-2
124 Psychotropic Drugs
125 Excitatory Amino Acid Antagonists
126 Anti-Anxiety Agents
127 Antioxidants Early Phase 1
128 Angiotensin II Type 1 Receptor Blockers Early Phase 1
129 Angiotensin Receptor Antagonists Early Phase 1
130 Dihydroxyphenylalanine Early Phase 1
131 Calcium, Dietary
132 Iron Supplement
133 Serotonin Uptake Inhibitors
134 Antidepressive Agents
135 Fibrinolytic Agents
136 Anticoagulants
137 Heparin, Low-Molecular-Weight
138 Senna
139 Sennoside A&B
140 Anti-Infective Agents, Local
141 Immunoconjugates
142 Vasodilator Agents
143 Mugwort
144 Adrenergic alpha-Agonists Early Phase 1
145 Adrenergic Agonists Early Phase 1
146 Central Nervous System Stimulants Early Phase 1
147 Melanocyte-Stimulating Hormones
148 Hormone Antagonists
149 Adrenocorticotropic Hormone
150 beta-Endorphin
151 omega-N-Methylarginine Early Phase 1
152 Vasoconstrictor Agents
153 Cardiotonic Agents
154 Protective Agents
155 Catechol
156 Hormones
157 Respiratory System Agents
158 Anti-Asthmatic Agents
159 Adrenergic beta-Agonists
160 Nasal Decongestants
161 Mydriatics
162 Sympathomimetics
163 Autoantibodies
164 Bronchodilator Agents
165 Analgesics
166 Narcotics
167 Analgesics, Opioid
168 Micronutrients
169 Trace Elements
170 Nutrients
171
Calcium Nutraceutical 7440-70-2 271
172
Serotonin Investigational, Nutraceutical 50-67-9 5202
173
Arginine Investigational, Nutraceutical Early Phase 1 74-79-3 6322

Interventional clinical trials:

(showing 108, show less)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Unknown status NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
2 Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment Completed NCT02171988 Phase 4 Propranolol;Bisoprolol;Propranolol+pyridostigmine;Bisoprolol+pyridostgmine
3 Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section Completed NCT02780245 Phase 4 Tranexamic Acid
4 A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome Unknown status NCT03365414 Phase 3 Normal Saline 0.9% Infusion Solution Bag
5 Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial) Completed NCT03182725 Phase 3 Ivabradine;Placebo
6 Role of Vitamin D (Alphacalcidol) Supplement to Reduce Pain and Cartilage Oligomeric Matrix Protein Serum Levels in Geriatric Knee Osteoarthritis Patients: A Randomized, Double-Blind, Placebo-Controlled Study Completed NCT04405960 Phase 3 Alfacalcidol 1 MCG Oral Capsule;Sugar pill
7 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
8 1/2 D-cycloserine Augmentation of CBT for Pediatric OCD Completed NCT01411774 Phase 3 d-cycloserine;Pill placebo
9 Kidney Dopamine Effects on Urinary Sodium Excretion in Postural Tachycardia Syndrome Active, not recruiting NCT00685919 Phase 2, Phase 3 Carbidopa;Placebo
10 The Effect of "Funny" Channel Blocker Ivabradine on Patients With Postural Tachycardia Syndrome. Unknown status NCT01761825 Phase 2 ivabradine
11 Einfluss Selektiver I(f)-Blockade Auf Orthostase-Toleranz Und Sympathikusaktivität Bei Gesunden Unknown status NCT00865917 Phase 2 beta-blocker (Metoprolol);I(f)-blocker (ivabradine);Placebo
12 Nasal Irrigation for Chronic Rhinosinusitis and Fatigue in Patients With Gulf War Illness Completed NCT01700725 Phase 2 Nasal Irrigation - Xylitol
13 D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder Completed NCT00864123 Phase 2 D-cycloserine;Placebo pill
14 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo
15 A Randomized Crossover Study of Propranolol Versus Ivabradine in Postural Tachycardia Syndrome (POTS) Recruiting NCT04186286 Phase 2 Ivabradine 4-week course;Propranolol 4-week course;Placebo 4-week course
16 IVIG (Gamunex-C) Study of Treatment for Autoimmune Neuropathic Dysautonomia/Postural Tachycardia (POTS) Enrolling by invitation NCT03919773 Phase 1, Phase 2 IVIG;Albumin
17 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Enrolling by invitation NCT03674541 Phase 2 Pyridostigmine Bromide;Placebo
18 A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) Terminated NCT01978535 Phase 1, Phase 2 Iron infusion;Normal saline infusion
19 A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist Terminated NCT03070730 Phase 1, Phase 2 Droxidopa;Atenolol;Placebos
20 The Renin-Aldosterone Axis in Postural Tachycardia Syndrome Completed NCT00962949 Phase 1 Angiotensin II
21 Autonomic Nervous System and Chronic Fatigue Syndrome Completed NCT00580619 Phase 1 L-NMMA trimethaphan;methyldopa
22 Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) Completed NCT00473928 Phase 1 POT-4
23 Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3) Active, not recruiting NCT03124355 Phase 1 placebo sugar pill;Pyridostigmine Pill;Galantamine Pill
24 Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Active, not recruiting NCT02854683 Phase 1 Normal Saline
25 Clinical Efficacy of High-Sodium Diet and External Abdominal Compression in the Treatment of Orthostatic Intolerance in POTS Terminated NCT01771484 Phase 1
26 The European Bifurcation Club Left Main Study: A Randomised Comparison of Single Versus Dual Stent Implantation for Distal Left Main True Coronary Bifurcation Lesions Unknown status NCT02497014
27 The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes: A Randomized Interventional Clinical Study Unknown status NCT02435589
28 Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS) Completed NCT01366963
29 Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Completed NCT00581022
30 Electroencephalographic (EEG) Characteristics of Postural Tachycardia Syndrome (POTS) and Syncope (Without POTS) During Head-upright Tilt Table Testing Completed NCT02167412
31 Gabapentin Treatment of Postural Tachycardia Syndrome (PoTS): a Pilot Study Completed NCT04345432 Gabapentin
32 Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome (POTS) Completed NCT01308099
33 Qualitative Sweat Distribution Among Youth With Postural Tachycardia Syndrome (POTS), Syncope, or Anxiety Completed NCT02329548
34 POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND GASTROINTESTINAL SYMPTOMS: Contribution of Gastrointestinal Peptides Completed NCT03263819
35 Local Vasoconstriction in Postural Tachycardia Syndrome Completed NCT01210430 Early Phase 1 Losartan;Ascorbic Acid (Vitamin C);Normal Saline
36 Renal Salt Handling in Postural Tachycardia Syndrome Following Dietary Dopa Administration Completed NCT01064739 Early Phase 1
37 Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients Completed NCT01795469
38 Tilt Table and Autonomic Testing in Suspected POTS Subjects Completed NCT01617616
39 Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia ("POTS" -- Postural Orthostatic Tachycardia Syndrome)Later in Life -- a Retrospective Analysis Completed NCT01367977
40 Evaluation of the Compensatory Reserve Index and Psychosocial Factors in Pediatric Autonomic Dysfunction Completed NCT03974737
41 Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome, Irritable Bowel Syndrome, Postural Orthostatic Tachycardia Syndrome, Functional Abdominal Pain or Chronic Nausea Completed NCT00728026
42 Effects of Exercise in Orthostatic Intolerance Completed NCT00770484 Propranolol then Placebo;Placebo then Propranolol
43 Clinical Autonomic Disorders: A Training Protocol Completed NCT02154009
44 Relationship of Autonomic Function to Hypnotic Susceptibility Completed NCT00061009
45 Evaluation of Effects of Fermented Dairy Products Containing Probiotics Alone or in Association With Fibers on Bowel Functions, Constipation Symptoms and Health Related Quality of Life in Adult Subjects With Moderate Constipation: an Exploratory Randomized Double-blind, Controlled Adaptive Study Completed NCT02461485
46 Association Between GI Microbiota, Low-grade Inflammation and Classical Pathophysiological Factors in Patients With Irritable Bowel Syndrome (IBS) and Effect of the Consumption of Activia on GI Symptoms Provoked by a Lactulose Challenge Test in IBS Patients Completed NCT01252550
47 Effect of the Consumption of Yogurt Fortified in Calcium and Vitamin D on the Circulating Levels of 25OHD in Postmenopausal Women Completed NCT02534064
48 A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia Completed NCT02341586
49 Exploratory Study Aiming at Assessing the Impact of Specific and Controlled Diets Combined With a Fermented Milk Product on Gas-related Symptoms and Associated Measurements in FGID and Non-FGID Subjects Completed NCT02936713
50 Evaluation of a 28-day Fermented Milk Product Consumption Twice Daily as Compared to a Non-fermented Milk Product on Intestinal Gas Production in Healthy Subjects High Dihydrogen Producers A Randomized, Controlled, Double-blind, Parallel Arms, Adaptive Study Completed NCT03015441
51 Impact of Pots-stroke Depression Treatment on Stroke Recurrence Completed NCT04776226 Citalopram
52 Pot-Cast: Thrombosis Prophylaxis During Plaster Cast Lower Leg Immobilisation: Determining the Balance Between Benefits and Risks Completed NCT01542762 LMWH
53 Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy: Determining the Balance Between Benefits and Risks Completed NCT01542723 LMWH
54 Senna Alata Leaf Decoction as a Treatment for Tinea Imbricata in an Indigenous Tribe in Southern Philippines :a Pilot Study Completed NCT03745183
55 Randomized Controlled Trial to Study the Effect of Consuming Food Cooked in Iron Utensils on Iron Status in Children With Iron Deficiency Anemia (IDA) Completed NCT01115023
56 Evaluating the Effect of Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Non Pitted Fluorosis Stains in Indian Population Completed NCT01733888
57 A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss Completed NCT03793153
58 Assessing the Health Impact of Advance Water Filters and Improved Cookstoves in Western Province, Rwanda: A Cluster-randomised Controlled Trial Completed NCT02239250
59 Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage: A Randomized Controlled Trial Completed NCT02229513
60 A Feasibility Study of the Ability of the Neural Prosthetic System to Provide Direct Brain Control of Extracorporeal Devices in Patients With Quadriplegia Due to High Spinal Cord Injury Completed NCT01849822
61 Yoga Nasal Irrigation in the Treatment of Chronic Tension Type Headache: Randomised Waitlist Controlled Trial Completed NCT04113512
62 Autonomic Determinants of Postural Tachycardia Syndrome (Acute Pilot Study 1) Recruiting NCT04050410 Early Phase 1 Moxonidine;Placebo
63 Cleveland Clinic Arrhythmia Biospecimen Repository (Cleveland Clinic Arrhythmia BioBank) Recruiting NCT00921986
64 Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome Recruiting NCT03261570 Early Phase 1 Pyridostigmine;Digoxin;Placebo
65 Muscular and Cutaneous Dysfunction in Postural Tachycardia Syndrome Recruiting NCT04170725
66 The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2) Recruiting NCT02673996 Phenylephrine;Isoproterenol
67 Double-Blind, Placebo-Controlled Study of Pyridostigmine in Postural Tachycardia Syndrome Recruiting NCT00409435 pyridostigmine;Placebo
68 Alterations of Attention in Patients With Postural Tachycardia Syndrome and Healthy Controls Depending on Body Position and Hydration Recruiting NCT03253120
69 Remote Self-training Program for Patients With Postural Orthostatic Tachycardia Syndrome (POTS) Recruiting NCT04603157
70 Long-term Effects of Transcutaneous Vagal Nerve Stimulation on Symptoms and Cardiovascular Autonomic Profile of Patients With Postural Orthostatic Tachycardia Syndrome (POTS) Recruiting NCT04632134
71 Understanding Impaired Concentration, Attentional Deficits and Their Pathophysiology in Postural Orthostatic Tachycardia Syndrome (POTS) and Other Autonomic Neuropathies (POTSKog-Study Aachen) Recruiting NCT03681080
72 Autonomic Neuropathy and Its Pathophysiology in Autoimmune Autonomic Neuropathies, Postural Orthostatic Tachycardia Syndrome and Ehlers Danlos Syndromes: Peripheral Autonomic Small Fiber Neuropathy or Central Autonomic Failure? Recruiting NCT04310644
73 Pathophysiology of Orthostatic Intolerance Recruiting NCT00608725 Intrinsic Heart Rate
74 Multicenter RCT Comparing Two Brushes of Different Diameters for Biliary Stenosis: RX Cytology Brush, BOSTON vs. Infinity® Brush, US Endoscopy. BIB Study (BIliary Brushing) Recruiting NCT04251013
75 Assessment of Changes in Vaginal Microbiota Profiles Before and After Vaginal Urogynecologic Surgery Recruiting NCT04301401
76 Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial Recruiting NCT04374084
77 A Feasibility Study of the Ability of the Neural Prosthetic System 2 to Provide Direct Closed Loop Cortical Control of Extracorporeal Devices Through the Use of Intracortical Microstimulation in Patients With Quadriplegia Recruiting NCT01964261
78 Quick-Wee Versus Bladder Stimulation to Collect Midstream Urine From Pre-continent Infants: a Randomized Controlled Trial Recruiting NCT04587999
79 Standing Cognition and Co-morbidities of POTS Evaluation Active, not recruiting NCT03602482
80 A Pilot Study of the Effect of Dietary Sodium Intake on Assessments of Vascular Endothelium Active, not recruiting NCT01550315
81 Body Compression in Postural Tachycardia Syndrome (POTS): Effects on Orthostatic Tolerance Active, not recruiting NCT03484273
82 Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome Active, not recruiting NCT02196376
83 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome Active, not recruiting NCT01563107
84 Dietary Salt in Postural Tachycardia Syndrome Active, not recruiting NCT01547117
85 Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome Active, not recruiting NCT02281097
86 Assessment of Inspiratory Breathing Devices to Improve Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome Active, not recruiting NCT00962728
87 Intravenous Saline on Exercise Tolerance in Orthostatic Intolerance Active, not recruiting NCT01000350 Saline
88 Assessment of Objective Sleep Disturbances in Orthostatic Intolerance Using Actigraphy Active, not recruiting NCT00692471
89 Acute Renal Salt Handling in Orthostatic Intolerance Active, not recruiting NCT00581633
90 Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome - Screening Protocol Active, not recruiting NCT01783288
91 Modafinil and Cognitive Function in Postural Tachycardia Syndrome Active, not recruiting NCT01988883 Early Phase 1 Placebo;Modafinil;Propranolol
92 Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome Participating in the Dietary Salt in Orthostatic Tachycardia Study. Active, not recruiting NCT01764711 Cosyntropin administration
93 Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome Active, not recruiting NCT03930914
94 Mechanisms of Vasovagal Syncope Active, not recruiting NCT01791816 Early Phase 1 Phenylephrine;L-Ng-monomethyl Arginine (L-NMMA)
95 A Clinical Study to Assess the Safety of Controlled Human Plasmodium Vivax Malaria Infection Through Experimental Sporozoite Infection of Healthy Malaria-naïve UK Adults, and to Characterise Parasite Growth and Immune Responses to P.Vivax Active, not recruiting NCT03377296
96 Validation of Norepinephrine Transporter (NET) mRNA as a Measure of Functional NET Expression in Postural Tachycardia Syndrome (POTS) Enrolling by invitation NCT03218761
97 Autoimmune Basis for Postural Tachycardia Syndrome Enrolling by invitation NCT02725060 phenylephrine;isoproterenol
98 Effects of Potted Mint Plants on Indoor Air Quality and the Concentration of Bacterium and Fungus, and Evaluation of Cardiovascular Health Enrolling by invitation NCT04484662
99 Autonomic Determinants of Postural Tachycardia Syndrome (Chronic Pilot Study 2) Not yet recruiting NCT04140721 Early Phase 1 Placebo oral tablet;Moxonidine Pill
100 Hypercapnia and Orthostatic Tolerance in Postural Orthostatic Tachycardia Syndrome Not yet recruiting NCT04271878
101 Neural Correlates of Cognitive Dysfunction in Postural Tachycardia Syndrome Not yet recruiting NCT04137757
102 Physical Activity as a Complementary Treatment in Postural Orthostatic Tachycardia Syndrome - Evaluation of a Structured Physical Activity Program in Clinical Practice Not yet recruiting NCT04702217
103 Coronary Artery Bifurcation Revascularization Without kIssing ballOon infLation by rEpoT: The CABRIOLET Study Not yet recruiting NCT03550196
104 Supplementation of Rheumatoid Arthritis Patients With Dietary Fibre to Improve Their Gut Microbiota Not yet recruiting NCT04421313 Dietary Fiber Supplementation
105 Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain Not yet recruiting NCT04827992 Medical Marijuana
106 Dopamine in Orthostatic Tolerance Terminated NCT00748228
107 Investigating the Neuropsychological Profile of Youth With Obsessive Compulsive Disorder (OCD) Terminated NCT02160431
108 Use of Cast Iron Pots to Improve Maternal Anemia Terminated NCT02341300

Search NIH Clinical Center for Postural Orthostatic Tachycardia Syndrome

Cochrane evidence based reviews: postural orthostatic tachycardia syndrome

Genetic Tests for Postural Orthostatic Tachycardia Syndrome

Anatomical Context for Postural Orthostatic Tachycardia Syndrome

MalaCards organs/tissues related to Postural Orthostatic Tachycardia Syndrome:

40
Heart, Eye, Temporal Lobe, Brain, Spinal Cord, Endothelial, Pituitary

Publications for Postural Orthostatic Tachycardia Syndrome

Articles related to Postural Orthostatic Tachycardia Syndrome:

(showing 456, show less)
# Title Authors PMID Year
1
Restless legs syndrome is increased in postural orthostatic tachycardia syndrome. 61
33231164 2021
2
Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. 61
33786700 2021
3
Further Observations on the Use of Pacemakers in Patients with Postural Orthostatic Tachycardia Syndrome with Demonstrated Asystole. 61
33777484 2021
4
Response to Letter: Postural Orthostatic Tachycardia Syndrome in Children-A Single-Center Study. 61
33661061 2021
5
Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. 61
33723532 2021
6
Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness : Consensus statement of the European Federation of Autonomic Societies (EFAS) endorsed by the American Autonomic Society (AAS) and the European Academy of Neurology (EAN). 61
33740206 2021
7
Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. 61
33752997 2021
8
Is postural orthostatic tachycardia syndrome (POTS) a central nervous system disorder? 61
33677650 2021
9
Prevalence of joint hypermobility syndromes in pediatric postural orthostatic tachycardia syndrome. 61
33388686 2021
10
Postural orthostatic tachycardia syndrome following open thoracoabdominal aortic aneurysm repair. 61
33623665 2021
11
Postural orthostatic tachycardia syndrome is associated with significant employment and economic loss. 61
33586284 2021
12
Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies. 61
33562074 2021
13
Autonomic dysfunction in childhood hypersomnia disorders. 61
33385777 2021
14
gAChR antibodies in children and adolescents with acquired autoimmune dysautonomia in Japan. 61
33621398 2021
15
Raising the bar in postural orthostatic tachycardia syndrome research: Evidence and challenges. 61
33714702 2021
16
Higher Quality Evidence to Guide Our Management of Postural Orthostatic Tachycardia Syndrome: A New Era? 61
33602469 2021
17
Postural orthostatic tachycardia syndrome - an 'invisible condition' with far-reaching consequences. 61
33544934 2021
18
Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndrome. 61
32757696 2021
19
Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. 61
33602468 2021
20
Supraventricular Tachycardia and Postural Orthostatic Tachycardia Syndrome Overlap: A Retrospective Study. 61
33654569 2021
21
Adalimumab as a potential treatment for postural orthostatic tachycardia syndrome. 61
33505857 2021
22
EMA's mishandling of an investigation into suspected serious neurological harms of HPV vaccines. 61
33514652 2021
23
Prevalence of gastrointestinal, cardiovascular, autonomic, and allergic manifestations in hospitalized patients with Ehlers-Danlos syndrome: a case-control study. 61
33410480 2021
24
Postural orthostatic tachycardia syndrome in patients of orthostatic intolerance symptoms: an ambispective study. 61
33490373 2021
25
Regional Gastrointestinal Transit and Contractility Patterns Vary in Postural Orthostatic Tachycardia Syndrome (POTS). 61
33428036 2021
26
Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome. 61
33478652 2021
27
Cardiovascular exercise as a treatment of postural orthostatic tachycardia syndrome: A pragmatic treatment trial. 61
33482385 2021
28
Mechanisms and management of gastrointestinal symptoms in postural orthostatic tachycardia syndrome. 61
33140561 2020
29
Increased Salt Intake for Orthostatic Intolerance Syndromes: A Systematic Review and Meta-Analysis. 61
32603788 2020
30
Dimensional latent factor structure of psychopathology in adults with chronic illness. 61
33271041 2020
31
Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. 61
32803794 2020
32
Comparisons of the Nonlinear Relationship of Cerebral Blood Flow Response and Cerebral Vasomotor Reactivity to Carbon Dioxide under Hyperventilation between Postural Orthostatic Tachycardia Syndrome Patients and Healthy Subjects. 61
33352894 2020
33
Cosegregation of postural orthostatic tachycardia syndrome, hypermobile Ehlers-Danlos syndrome, and mast cell activation syndrome. 61
32798618 2020
34
Was the diagnosis really postural orthostatic tachycardia syndrome? 61
33191893 2020
35
A Pilot Study using the Compensatory Reserve Index to evaluate individuals with Postural Orthostatic Tachycardia syndrome. 61
32993834 2020
36
Treatment of Postural Orthostatic Tachycardia Syndrome With Medication: A Systematic Review. 61
32838632 2020
37
New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection. 61
33262898 2020
38
Characterization of Blood Pressure and Heart Rate Oscillations of POTS Patients via Uniform Phase Empirical Mode Decomposition. 61
32078525 2020
39
Postural Orthostatic Tachycardia Syndrome and Disordered Eating: Clarifying the Overlap. 61
33181565 2020
40
Reductions in Cerebral Blood Flow Can Be Provoked by Sitting in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. 61
33050553 2020
41
Psychiatric Disorder in Postural Orthostatic Tachycardia Syndrome and Ehlers-Danlos Syndrome-Hypermobility Type. 61
33125200 2020
42
Quantitative sensory testing predicts histological small fiber neuropathy in postural tachycardia syndrome. 61
33299671 2020
43
Work Ability Assessment and Its Relationship with Cardiovascular Autonomic Profile in Postural Orthostatic Tachycardia Syndrome. 61
33114659 2020
44
The incidence of postural orthostatic tachycardia syndrome in the population of Zagreb, Croatia. 61
33150760 2020
45
Postural Orthostatic Tachycardia Syndrome Misdiagnosed as Anxiety: A Case Report with a Review of Therapy and Pathophysiology. 61
33178533 2020
46
Psychological correlates of patients with postural orthostatic tachycardia syndrome (POTS). 61
32544859 2020
47
Bier anemic spots, cyanosis, and urticaria-like eruption (BASCULE) syndrome: Report of two new cases and literature review. 61